Patents Assigned to Seattle Biomedical Research Institute
-
Patent number: 10272145Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.Type: GrantFiled: October 19, 2016Date of Patent: April 30, 2019Assignees: Rhode Island Hospital, Seattle Biomedical Research InstituteInventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
-
Patent number: 10213502Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.Type: GrantFiled: May 26, 2017Date of Patent: February 26, 2019Assignees: Rhode Island Hospital, Seattle Biomedical Research InstituteInventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
-
Publication number: 20180356419Abstract: The present application relates generally to biomarkers for tuberculosis (TB) infection and disease and methods of detection thereof. In various embodiments, the invention relates to one or more biomarkers, biomarker panels, methods, devices, reagents, systems, and kits for detecting and/or characterizing TB infection and/or disease.Type: ApplicationFiled: May 7, 2016Publication date: December 13, 2018Applicants: SOMALOGIC, INC., UNIVERSITY OF CAPE TOWN, SEATTLE BIOMEDICAL RESEARCH INSTITUTE D/B/A THE CENTER FOR INFECTIOUS DISEASE RESEARCHInventors: Thomas HRAHA, David STERLING, Urs A. OCHSNER, Nebojsa JANJIC, Thomas Jens SCRIBA, Adam Garth PENN-NICHOLSON, Willem Albert HANEKOM, Daniel Edward ZAK, Ethan Greene THOMPSON
-
Publication number: 20170326219Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.Type: ApplicationFiled: May 26, 2017Publication date: November 16, 2017Applicants: Rhode Island Hospital, Seattle Biomedical Research InstituteInventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
-
Patent number: 9662379Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.Type: GrantFiled: November 30, 2012Date of Patent: May 30, 2017Assignees: Rhode Island Hospital, Seattle Biomedical Research InstituteInventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
-
Publication number: 20170056422Abstract: The present disclosure provides for methods of addressing the devastating effects of malaria infection by mosquito-borne Plasmodium parasites. The methods include the administration of an effective amount of at least one pro-apoptotic agent and the administration of an effective amount of at least one p53 activator. The at least one pro-apoptotic agent can be administered concurrently with, prior to, or subsequent to the at least one p53 activator. The at least one pro-apoptotic agent and/or at least one p53 activator can be administered concurrently with, prior to, or subsequent to exposure of a hepatocyte (in vivo or in vitro) by a Plasmodium parasite. In some embodiments, the administration of the at least one pro-apoptotic agent combined with the administration of the at least one p53 activator results in clearance of hypnozoite stage of P. vivax or P. ovale, and thus prevents relapse of symptoms and disease from the infection of these parasites.Type: ApplicationFiled: May 7, 2015Publication date: March 2, 2017Applicant: Seattle Biomedical Research InstituteInventors: Alexis Kaushansky, Stefan H.I. Kappe, Alyse N. Douglass, Heather S. Kain
-
Publication number: 20150377880Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.Type: ApplicationFiled: December 10, 2013Publication date: December 31, 2015Applicants: Seattle Biomedical Research Institute, The University of QueenslandInventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J.A. Shiddiky, Matt Trau
-
Publication number: 20150315632Abstract: Disclosed are compositions and methods for detecting the presence of viable cells in a sample. Included are compositions and methods for increasing the sensitivity of a nucleic acid amplification test for determining the presence of at least one target microorganism in a sample. Also disclosed are compositions and methods for detecting ribosomal RNA precursors (pre-rRNA) as dynamic indicators of viable microorganisms in a sample.Type: ApplicationFiled: July 15, 2015Publication date: November 5, 2015Applicants: University of Washington, Seattle Biomedical Research InstituteInventors: Gerard A. Cangelosi, John Scott Meschke, Kris Weigel
-
Patent number: 9115407Abstract: Disclosed are compositions and methods for detecting the presence of viable cells in a sample. Included are compositions and methods for increasing the sensitivity of a nucleic acid amplification test for determining the presence of at least one target microorganism in a sample. Also disclosed are compositions and methods for detecting ribosomal RNA precursors (pre-rRNA) as dynamic indicators of viable microorganisms in a sample.Type: GrantFiled: December 10, 2009Date of Patent: August 25, 2015Assignees: University of Washington, Seattle Biomedical Research InstituteInventors: Gerard A. Cangelosi, John Scott Meschke, Kris Weigel
-
Patent number: 8318183Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.Type: GrantFiled: March 11, 2010Date of Patent: November 27, 2012Assignees: Seattle Biomedical Research Institute, The United States of America, as Represented by the Secretary of the Army, on Behalf of the Walter Reed Army Institute of Research, Philadelphia Health & Education CorporationInventors: Patrick Duffy, Stefan H. I. Kappe, Urszula Krzych, Donald G. Heppner, Lawrence W. Bergman, Vladislav A. Malkov, Alice Tarun, Jason P. Wendler, Igor Bacik
-
Patent number: 8168166Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.Type: GrantFiled: May 6, 2008Date of Patent: May 1, 2012Assignees: Seattle Biomedical Research Institute, Walter and Eliza Hall Institute of Medical ResearchInventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller, Kelley van Buskirk, Mehdi Labaied, Ahmed Sayed Ibrahim Aly, Alan Frederick Cowman, Alexander Gerd Maier
-
Publication number: 20120094285Abstract: Disclosed are compositions and methods for detecting the presence of viable cells in a sample. Included are compositions and methods for increasing the sensitivity of a nucleic acid amplification test for determining the presence of at least one target microorganism in a sample. Also disclosed are compositions and methods for detecting ribosomal RNA precursors (pre-rRNA) as dynamic indicators of viable microorganisms in a sample.Type: ApplicationFiled: December 10, 2009Publication date: April 19, 2012Applicants: Seattle Biomedical Research Institute, University of WashingtonInventors: Gerard A Cangelosi, John Scott Meschke, Kris Weigel
-
Patent number: 8012493Abstract: The invention provides isolated placental P. falciparum polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-4 and 6-24, and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the placental P. falciparum polypeptides of the invention, compositions comprising one or more placental P. falciparum polypeptides of the invention, methods for inducing an immune response against the placental P. falciparum polypeptides, and methods for treating and diagnosing placental malaria.Type: GrantFiled: December 8, 2009Date of Patent: September 6, 2011Assignees: Seattle Biomedical Research Institute, The United States of America as represented by the Secretary of the ArmyInventors: Michal Fried, Patrick E Duffy, Susan Francis, Jason P Wendler, Theonest K Mutabingwa, Andrew Oleinikov
-
Publication number: 20100172929Abstract: The invention provides isolated placental P. falciparum polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-4 and 6-24, and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the placental P. falciparum polypeptides of the invention, compositions comprising one or more placental P. falciparum polypeptides of the invention, methods for inducing an immune response against the placental P. falciparum polypeptides, and methods for treating and diagnosing placental malaria.Type: ApplicationFiled: December 8, 2009Publication date: July 8, 2010Applicants: SEATTLE BIOMEDICAL RESEARCH INSTITUTE, UNITED STATES ARMYInventors: Michal Fried, Patrick E. Duffy, Susan Francis, Jason P. Wendler, Theonest K. Mutabingwa, Andrew Oleinikov
-
Publication number: 20100166794Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.Type: ApplicationFiled: March 11, 2010Publication date: July 1, 2010Applicants: SEATTLE BIOMEDICAL RESEARCH INSTITUTE, The USA, as Represented by the Secretary of the Army,on Behalf of the Walter Reed, Philadelphia Health & Education Corporation, d/b/a Drexel University College of Medicine "DUCOM"Inventors: Patrick Duffy, Stefan H.I. Kappe, Urszula Krzych, Donald G. Heppner, JR., Lawrence W. Bergman, Vladislav A. Malkov, Alice Tarun, Jason W. Wendler, Igor Bacik
-
Patent number: 7722889Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.Type: GrantFiled: September 29, 2006Date of Patent: May 25, 2010Assignees: Seattle Biomedical Research Institute, The United States of America as represented by the Secretary of the ArmyInventors: Patrick Duffy, Urszula Krzych, Donald G. Heppner, Jr., Vladislav A. Malkov, Jason W. Wendler, Igor Bacik
-
Patent number: 7722860Abstract: The invention provides methods for inducing an immune response in a vertebrate host against a protozoan parasite, comprising administering to the host a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host. Representative protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida. The vertebrate host may be a mammal or a bird.Type: GrantFiled: June 22, 2005Date of Patent: May 25, 2010Assignee: Seattle Biomedical Research InstituteInventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller
-
Patent number: 7718165Abstract: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.Type: GrantFiled: December 20, 2004Date of Patent: May 18, 2010Assignees: Seattle Biomedical Research Institute, Ruprecht-Karls-Universitat HeidelbergInventors: Stefan H. I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller
-
Patent number: 7655247Abstract: The invention provides isolated placental P. falciparum polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-4 and 6-24, and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the placental P. falciparum polypeptides of the invention, compositions comprising one or more placental P. falciparum polypeptides of the invention, methods for inducing an immune response against the placental P. falciparum polypeptides, and methods for treating and diagnosing placental malaria.Type: GrantFiled: January 3, 2008Date of Patent: February 2, 2010Assignees: Seattle Biomedical Research Institute, The United States of America as represented by the ArmyInventors: Michal Fried, Patrick E. Duffy, Susan Francis, Jason P. Wendler, Theonest K. Mutabingwa, Andrew Oleinikov
-
Publication number: 20090017055Abstract: The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.Type: ApplicationFiled: September 29, 2006Publication date: January 15, 2009Applicants: SEATTLE BIOMEDICAL RESEARCH INSTITUTE, REED ARMY INSTITUTE OF RESEARCH, PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A/ DREXEL UNIVERSITY COLLEGE OF MEDICINE DUCOMInventors: Patrick Duffy, Stefan H. I. Kappe, Urszula Krzych, Donald G. Heppner, JR., Lawrence W. Bergman, Vladislav A. Malkov, Alice Tarun, Jason W. Wendler, Igor Bacik